• Je něco špatně v tomto záznamu ?

The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry

M. Skácelová, L. Nekvindová, H. Mann, J. Závada, Z. Křístková, J. Vencovský, K. Pavelka, P. Horák, ATTRA Registry

. 2022 ; 42 (5) : 803-814. [pub] 20220326

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018664
E-zdroje Online Plný text

NLK ProQuest Central od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-12-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-03-01 do Před 1 rokem

Odkazy

PubMed 35338383
DOI 10.1007/s00296-021-05072-2
Knihovny.cz E-zdroje

The study aimed to compare treatment retention for first-line TNF inhibitor (TNFi) in the ATTRA registry patients receiving either combination with conventional synthetic DMARDs or TNFi as monotherapy. A retrospective multicenter study analyzed data of all adult patients with rheumatoid arthritis (n = 3032) starting TNF inhibitor as the first-line biological therapy in combination with csDMARDs or in monotherapy from January 1st 2012 to December 31st 2020. Kaplan-Meier method was employed to calculate drug retentions. Survival curves of treatment retentions were compared through Log-rank test between the studied subgroups. The hazard ratio for drug discontinuation was assessed through univariate cox regression models. In patients who started the first line TNFi therapy, the median treatment retention was 47.7 (42.2; 53.1) months for combination therapy and 22.7 (14.9; 30.6) months for TNFi monotherapy (p < 0.001). Estimated one-year survival was higher in patients on TNFi combined with csDMARDs as compared with TNFi monotherapy (75.3% vs 65.7%); two-year survival rate was 63.2% vs 49.2%, three-year survival rate was 55.4% vs 42.4% and five-year survival 44.9% vs 26.4% of patients. The estimated survival on the first TNFi was higher in patients taking combination therapy with methotrexate than with other csDMARDs (p = 0.003). Use of csDMARDs co-medication was associated with significantly better first TNFi drug survival compared to monotherapy. The combination of TNFi with MTX is more effective than the combination with leflunomide, which did not demonstrate a significant effect.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018664
003      
CZ-PrNML
005      
20220804134942.0
007      
ta
008      
220720s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00296-021-05072-2 $2 doi
035    __
$a (PubMed)35338383
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Skácelová, Martina $u Third Department of Internal Medicine-Nephrology, Rheumatology and Endrocrinology, Olomouc University Hospital, I.P.Pavlova 6, 77900, Olomouc, Czech Republic $u Faculty of Medicine and Dentistry, Palacký University Olomouc, I.P.Pavlova 6, 77900, Olomouc, Czech Republic
245    14
$a The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry / $c M. Skácelová, L. Nekvindová, H. Mann, J. Závada, Z. Křístková, J. Vencovský, K. Pavelka, P. Horák, ATTRA Registry
520    9_
$a The study aimed to compare treatment retention for first-line TNF inhibitor (TNFi) in the ATTRA registry patients receiving either combination with conventional synthetic DMARDs or TNFi as monotherapy. A retrospective multicenter study analyzed data of all adult patients with rheumatoid arthritis (n = 3032) starting TNF inhibitor as the first-line biological therapy in combination with c $a The study aimed to compare treatment retention for first line TNF inhibitor TNFi in the ATTRA registry patients receiving either combination with conventional synthetic DMARDs or TNFi as monotherapy A retrospective multicenter study analyzed data of all adult patients with rheumatoid arthritis n 3032 starting TNF inhibitor as the first line biological therapy in combination with csDMARDs $a The study aimed to compare treatment retention for first-line TNF inhibitor (TNFi) in the ATTRA registry patients receiving either combination with conventional synthetic DMARDs or TNFi as monotherapy. A retrospective multicenter study analyzed data of all adult patients with rheumatoid arthritis (n = 3032) starting TNF inhibitor as the first-line biological therapy in combination with csDMARDs or in monotherapy from January 1st 2012 to December 31st 2020. Kaplan-Meier method was employed to calculate drug retentions. Survival curves of treatment retentions were compared through Log-rank test between the studied subgroups. The hazard ratio for drug discontinuation was assessed through univariate cox regression models. In patients who started the first line TNFi therapy, the median treatment retention was 47.7 (42.2; 53.1) months for combination therapy and 22.7 (14.9; 30.6) months for TNFi monotherapy (p < 0.001). Estimated one-year survival was higher in patients on TNFi combined with csDMARDs as compared with TNFi monotherapy (75.3% vs 65.7%); two-year survival rate was 63.2% vs 49.2%, three-year survival rate was 55.4% vs 42.4% and five-year survival 44.9% vs 26.4% of patients. The estimated survival on the first TNFi was higher in patients taking combination therapy with methotrexate than with other csDMARDs (p = 0.003). Use of csDMARDs co-medication was associated with significantly better first TNFi drug survival compared to monotherapy. The combination of TNFi with MTX is more effective than the combination with leflunomide, which did not demonstrate a significant effect.
650    _2
$a dospělí $7 D000328
650    12
$a antirevmatika $x škodlivé účinky $7 D018501
650    12
$a revmatoidní artritida $x chemicky indukované $x diagnóza $x farmakoterapie $7 D001172
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a lidé $7 D006801
650    _2
$a methotrexát $x škodlivé účinky $7 D008727
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a inhibitory TNF $x terapeutické užití $7 D000079424
650    _2
$a TNF-alfa $x terapeutické užití $7 D014409
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Nekvindová, Lucie $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Mann, Heřman $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Závada, Jakub $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Křístková, Zlatuše $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Vencovský, Jiří $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pavelka, Karel $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Horák, Pavel $u Third Department of Internal Medicine-Nephrology, Rheumatology and Endrocrinology, Olomouc University Hospital, I.P.Pavlova 6, 77900, Olomouc, Czech Republic. Pavel.horak@fnol.cz $u Faculty of Medicine and Dentistry, Palacký University Olomouc, I.P.Pavlova 6, 77900, Olomouc, Czech Republic. Pavel.horak@fnol.cz $1 https://orcid.org/000000022394064X $7 xx0032850
710    2_
$a ATTRA Registry
773    0_
$w MED00004228 $t Rheumatology international $x 1437-160X $g Roč. 42, č. 5 (2022), s. 803-814
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35338383 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134936 $b ABA008
999    __
$a ok $b bmc $g 1822335 $s 1169907
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 42 $c 5 $d 803-814 $e 20220326 $i 1437-160X $m Rheumatology international $n Rheumatol Int $x MED00004228
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace